VII International Heart Failure Summit
Heart Failure, Cardiomyopathies and Pulmonary Hypertension Management in the Polypharmacy and Device Era
Virtual and In-Person
October 17-October 21, 2022
Polypharmacy 1, 2, 3, 4, 5 ,6 …. Therapies in Heart Failure
Cardiometabolic disease, Diabetes, Kidney and Heart Failure (iSGLT2, GLP-1 agonist)
Ablattion or not Ablation of atrial fibrillation in Heart Failure?
Heart Failure as prothrombotic disease
Cardiomyopathies and Heart Failure
Amyloidosis. Newer approaches. Early diagnosis and treatment
Devices and remote monitoring for HFREF & HFPEF
Preserved EF HF. Different Phenotypes. Newer therapies.
New Cardiogenic Shock Guidelines
Novel strategies in Pulmonary Hypertension
Cardio-Oncology. Approach in cancer patients
Interventional Heart Failure
Percutaneous Valvular Interventions
Arrhythmias management in Heart Failure
Multimodality imaging in HF.
Hypertrophic Cardiomyopathy (HCOM/HCM)
Percutaneous and Durables Ventricular Assist Devices
Total Artificial Heart
Alejandro (Alex) Barbagelata, MD, FAHA, FSCAI, FICA, MTSAC
Dr. Barbagelata is an invasive cardiologist with Heart Failure longstanding expertise. He was past director of the Heart failure, assist devices and Transplant at University of Texas medical branch. Professor of Medicine/Cardiology Duke University School of Medicine and Board of Directors of DUCCS (Duke University Cardiovascular Society). Member of the International Speaker Bureau of the American Heart Association. He Co-direct the Heart Failure program at the Catholic University and has privileges in several centers in private practice